GlassScriptPhysician profile
Allan A Weber
NPI 1356382618
$113,237.77
in general payments reported to CMS, 2019-2025
50 companies · $19K in 2025
The $19K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $22K · 2021: $15K · 2022: $12K · 2023: $8,441 · 2024: $7,550 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $6,012 · Education: $259 · Travel and Lodging: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,818.75 |
| Food and Beverage | $6,011.72 |
| Education | $259.27 |
| Travel and Lodging | $210.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45,298.05 | 2021-2025 | Qulipta, Ubrelvy |
| Acorda Therapeutics, INC | $36,872.74 | 2019-2021 | |
| Allergan, INC. | $15,306.11 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $5,665.63 | 2019-2024 | Nuplazid |
| Emd Serono, INC. | $2,412.38 | 2019-2025 | Mavenclad, Mavenclad |
| Amneal Pharmaceuticals LLC | $983.30 | 2019-2025 | Rytary, Ongentys, Crexont |
| Supernus Pharmaceuticals, INC. | $744.36 | 2019-2021 | |
| Ucb, INC. | $711.83 | 2019-2021 | |
| Sk Life Science, INC. | $632.48 | 2020-2025 | Xcopri |
| Lilly USA, LLC | $520.27 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Novartis Pharmaceuticals Corporation | $378.02 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $333.64 | 2019-2025 | Austedo Xr, Austedo Xr |
| Genentech USA, INC. | $272.15 | 2019-2022 | |
| Genzyme Corporation | $261.59 | 2019-2021 | |
| Celgene Corporation | $240.20 | 2021-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.